Interacting Drugs |
Quinidine vs Dabigatran Etexilate |
Security Level |
|
Mechanism |
Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. |
Management |
Dabigatran dose reductions may be needed. According to Canadian labeling, dabigatran dose for prevention of venous thromboembolism post hip or knee replacement should be reduced to 150 mg/day in patients receiving amiodarone, verapamil, or quinidine. |
Quinidine vs Dabigatran Etexilate
Post Review about Quinidine vs Dabigatran Etexilate Click here to cancel reply.
Other Interactions of Quinidine
Other Interactions of Dabigatran Etexilate
Quinidine vs Dabigatran Etexilate
Interacting Drugs |
Quinidine vs Dabigatran Etexilate |
Security Level |
|
Mechanism |
Dabigatran Etexilate: QuiNIDine may increase the serum concentration of Dabigatran Etexilate. |
Management |
Canadian (but not U.S.) prescribing information recommends dosing dabigatran 2 hours prior to quinidine, and limiting dabigatran VTE prevention dose post hip/knee replacement to 150 mg/day in patients receiving quinidine. |
No comments yet.
Post Review about Quinidine vs Dabigatran Etexilate Click here to cancel reply.
Other Interactions of Quinidine
Other Interactions of Dabigatran Etexilate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.